Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic spleen aminopeptide oral solution in seasonal allergic rhinitis (Hohhot 2024 extension)
ChiCTR2400084502Phase 4Completed
- Sponsor
- Beijing Shijitan Hospital
- Start
- Apr 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of spleen polypeptide in allergic rhinitis (AR), sponsored by Beijing Shijitan Hospital. Primary endpoint: Risk of seasonal allergic rhinitis after pollen concentration adjustment compared to 2023. Started Apr 2024; status: completed.
02
Drugs
spleen polypeptide
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on ChiCTR2400084502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084502.